Published in Ann N Y Acad Sci on November 01, 2005
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol (2012) 1.82
Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat Methods (2013) 1.58
Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol (2011) 1.36
18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers. Cancer Res (2011) 1.36
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One (2009) 1.25
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene (2013) 1.16
c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther (2008) 1.15
B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res (2012) 1.15
NFATc1 affects mouse splenic B cell function by controlling the calcineurin--NFAT signaling network. J Exp Med (2011) 1.15
Vitamin C restores healthy aging in a mouse model for Werner syndrome. FASEB J (2009) 1.13
The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia (2009) 1.08
Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. Am J Transl Res (2010) 0.95
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol (2010) 0.93
PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer. J Natl Cancer Inst (2014) 0.90
MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation. Oncotarget (2015) 0.86
Subset of Suz12/PRC2 target genes is activated during hepatitis B virus replication and liver carcinogenesis associated with HBV X protein. Hepatology (2012) 0.86
Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol (2011) 0.85
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med (2016) 0.85
Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia (2015) 0.81
Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model. Clin Cancer Res (2016) 0.79
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. J Mol Diagn (2014) 0.78
Microenvironment abnormalities and lymphomagenesis: Immunological aspects. Semin Cancer Biol (2015) 0.75
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res (1995) 7.95
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A (1992) 6.37
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Drosophila myc regulates cellular growth during development. Cell (1999) 5.66
Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ (1997) 5.14
Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer (2005) 4.66
Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. Nature (1989) 4.65
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol (2001) 4.22
Myc activates telomerase. Genes Dev (1998) 3.74
TGFbeta influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol (2001) 3.69
The myc oncogene: MarvelouslY Complex. Adv Cancer Res (2002) 3.68
Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A (2000) 3.38
Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A (2001) 3.02
Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer (2004) 2.83
A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem (2003) 2.69
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09
A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A (1993) 1.91
Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev (2003) 1.88
Myc represses the growth arrest gene gadd45. Oncogene (1997) 1.86
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene (2002) 1.70
A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. Proc Natl Acad Sci U S A (2000) 1.61
Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res (2000) 1.55
Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood (2002) 1.48
Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ (1999) 1.47
Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology (2005) 1.41
Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res (2005) 1.29
Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res (1996) 1.15
Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell (2004) 1.10
Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood (2000) 0.98
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A (2009) 3.76
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
The myc-miR-17~92 axis blunts TGF{beta} signaling and production of multiple TGF{beta}-dependent antiangiogenic factors. Cancer Res (2010) 2.13
Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol Cell Biol (2006) 2.01
Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. Proc Natl Acad Sci U S A (2005) 1.91
Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol (2004) 1.90
ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest (2012) 1.85
A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene (2002) 1.70
An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth. Cancer Biol Ther (2003) 1.52
Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood (2002) 1.48
Lathosterolosis: an inborn error of human and murine cholesterol synthesis due to lathosterol 5-desaturase deficiency. Hum Mol Genet (2003) 1.45
B cell-specific loss of histone 3 lysine 9 methylation in the V(H) locus depends on Pax5. Nat Immunol (2004) 1.34
Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res (2007) 1.30
Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res (2005) 1.29
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst (2009) 1.19
Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells. Cancer Res (2005) 1.16
c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther (2008) 1.15
p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res (2011) 1.14
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest (2012) 1.09
B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling. J Clin Invest (2007) 1.05
The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood (2013) 0.96
Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. RNA (2012) 0.95
Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther (2007) 0.93
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
Regulation of CLU gene expression by oncogenes and epigenetic factors implications for tumorigenesis. Adv Cancer Res (2009) 0.93
Heavy neurofilament accumulation and alpha-spectrin degradation accompany cerebellar white matter functional deficits following forebrain fluid percussion injury. Exp Neurol (2006) 0.86
Inhibition of the single downstream target BAG1 activates the latent apoptotic potential of MYC. Mol Cell Biol (2011) 0.85
B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages. Exp Cell Res (2006) 0.83
Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression. J Natl Cancer Inst (2014) 0.82
Epigenetic histone modifications do not control Igkappa locus contraction and intranuclear localization in cells with dual B cell-macrophage potential. J Immunol (2006) 0.81
PAX5 and B-cell neoplasms: transformation through presentation. Future Oncol (2008) 0.79
Infection & neoplastic growth 101: the required reading for microbial pathogens aspiring to cause cancer. Cancer Treat Res (2006) 0.78
The long reach of noncoding RNAs. Nat Genet (2011) 0.78
MKK6 phosphorylation regulates production of superoxide by enhancing Rac GTPase activity. Antioxid Redox Signal (2007) 0.77
Aiding and ABT'ing Treatment for Glioblastoma. Cancer Biol Ther (2007) 0.77
Kit-activating mutations in AML: lessons from PU.1-induced murine erythroleukemia. Cancer Biol Ther (2006) 0.75